OCTREOTIDE

Summary

Octreotide is a long-acting synthetic analog of the hormone somatostatin and an established pharmaceutical peptide ^[1,2]. It is developed and approved to treat acromegaly and neuroendocrine tumors, and octreotide-based radioactive conjugates are used clinically to detect small neuroendocrine tumor sites ^[1]. Beyond these labeled uses, it is applied off-label across several conditions: subcutaneous or intravenous octreotide reduces drainage in chylothorax patients who fail conservative treatment, potentially shortening hospital stay ^[2], and it can control hypoglycemic symptoms in congenital hyperinsulinism and in insulinoma patients refractory to or intolerant of diazoxide, though it may worsen hypoglycemia by suppressing glucagon and growth hormone ^[4]. It is also used in palliative and symptom-management settings ^[3]. The evidence base is robust, with octreotide functioning as a well-characterized approved therapeutic with broad clinical use.

Sources

1. 1. Octreotide and Octreotide-derived delivery systems Journal of drug targeting, 2023.
2. 2. Octreotide Neonatal network : NN, 2006.
3. 3. Octreotide Journal of pain and symptom management, 2010.
4. 4. Octreotide in hyperinsulinism The Annals of pharmacotherapy, 1997.

For educational purposes only.